<DOC>
	<DOCNO>NCT00718393</DOCNO>
	<brief_summary>Amyotrophic lateral sclerosis uniformly progressive fatal neurodegenerative disorder know cure . In novel attempt widen search potential therapeutic agent , NINDS- lead cooperative group perform in-vitro screening program 1040 FDA approve drug 28 assay relevant various neurodegenerative disorder . Several cephalosporin show hit ALS relevant assay . Efficacy note model suggest increased expression astrocytic glutamate transporter , EAAT2 , well model superoxide dismutase mediate toxicity . Ceftriaxone third generation cephalosporin good CNS penetration , long half-life , effective type ALS assay . Ceftriaxone calcium binding activity , antioxidant property , rescue motor neuron culture chronic glutamate toxicity . Since completion original NINDS screen , Ceftriaxone show increase three fold EAAT2 activity rodent brain , due ceftriaxone 's ability increase EAAT2 promotor activation This program use ceftriaxone ALS compassionate care . Currently ceftriaxone approve U.S. Food Drug Administration ( FDA ) treat bacterial infection treat ALS . However , ongoing phase I study -by NEALS Consortium National Institute Health- three cohort -a placebo group two group receive either 2 4 gram ceftriaxone daily- . Unfortunately limited number patient enrol next phase project undertaken next year . At point ALS patient unable participate Phase I trial unlikely alive next phase study begin . Some patient want receive drug willing pay drug nursing care . We therefore request compassionate use protocol patient request medication willing pay drug nursing care administer . Dr. Terry Heiman-Patterson supervise administration safety monitor include labs renal hepatic function well IV site inspection .</brief_summary>
	<brief_title>Compassionate Use Ceftriaxone Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<criteria>Diagnosis definite probable ALS El Escorial Criteria Participants must medically able undergo study procedure Subjects must register nurse administer drug daily also inspect IV site Not Pregnant Willing pay cost drug , administration , safety test Able give inform consent Patients diagnosed ALS physician Patients unable give inform consent Patients history sensitivity cephalosporin penicillin antibiotic ( Ancef , Keflex , Ceclor , Ceftin , Lorabid , Suprax , Fortaz ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Cerebrospinal Fluid</keyword>
	<keyword>Neurodegenerative Disease</keyword>
	<keyword>Motor Neuron Disease</keyword>
	<keyword>Autonomic Nervous System</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Movement Disorders</keyword>
</DOC>